Category

UF Innovate | Accelerate

Satlantis, LLC, Announces Strategic Investment

UF startup Satlantis, LLC ("Satlantis"), a US technology leader in high precision miniaturized satellites and cameras is pleased to announce a strategic investment from Encino Environmental Holdings, LLC ("Encino"). This investment will allow Satlantis to accelerate the commercialization of its satellite-based greenhouse gas (GHG) monitoring technology and develop new products and services for the North American market.

1000X More Efficient Neural Networks: Building an Artificial Brain With 86 Billion Physical (but Not Biological) Neurons

What if in our attempt to build artificial intelligence we don’t simulate neurons in code and mimic neural networks in Python, but instead build actual physical neurons connected by physical synapses in ways very similar to our own biological brains? That’s precisely what UF startup Rain Neuromorphics, is trying to do: build a non-biological yet very human-style artificial brain.

Lacerta Therapeutics Expands Executive Leadership Team

UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.

Fitness App FitOn Raises $40M, Acquires Corporate Wellness Platform Peerfit

Digital fitness and wellness company FitOn has raised $40 million in Series C funding led by Delta-v Capital, the company announced on Tuesday. FitOn is also expanding its reach in wellness by acquiring Tampa-based corporate wellness platform Peerfit, a UF startup that incubated at UF Innovate | Accelerate at The Hub.

TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial

TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.